OBJECTIVE: Studies have demonstrated low concentrations of gamma-aminobutyric acid (GABA) in the plasma and CSF of individuals with major depression, and low GABA concentrations have also been found in the occipital cortex of depressed subjects. The goal of this study was to determine whether these occipital cortex GABA concentrations are altered after administration of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression. METHOD: By means of proton magnetic resonance spectroscopy, occipital cortex GABA concentrations were measured in 11 medication-free depressed patients before initiation of treatment with SSRI medications and after an average of 2 months of treatment. RESULTS: A significant increase in occipital cortex GABA concentrations was seen after SSRI treatment. CONCLUSIONS: SSRI treatment of major depression is associated with increased occipital cortex GABA concentrations. This appears to result in a normalization of low pretreatment GABA concentrations, an effect that may contribute to a common mechanism of antidepressant action.
OBJECTIVE: Studies have demonstrated low concentrations of gamma-aminobutyric acid (GABA) in the plasma and CSF of individuals with major depression, and low GABA concentrations have also been found in the occipital cortex of depressed subjects. The goal of this study was to determine whether these occipital cortex GABA concentrations are altered after administration of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression. METHOD: By means of proton magnetic resonance spectroscopy, occipital cortex GABA concentrations were measured in 11 medication-free depressedpatients before initiation of treatment with SSRI medications and after an average of 2 months of treatment. RESULTS: A significant increase in occipital cortex GABA concentrations was seen after SSRI treatment. CONCLUSIONS: SSRI treatment of major depression is associated with increased occipital cortex GABA concentrations. This appears to result in a normalization of low pretreatment GABA concentrations, an effect that may contribute to a common mechanism of antidepressant action.
Authors: Chris C Streeter; Theodore H Whitfield; Liz Owen; Tasha Rein; Surya K Karri; Aleksandra Yakhkind; Ruth Perlmutter; Andrew Prescot; Perry F Renshaw; Domenic A Ciraulo; J Eric Jensen Journal: J Altern Complement Med Date: 2010-08-19 Impact factor: 2.579
Authors: He Zhu; Beata Karolewicz; Emily Nail; Craig A Stockmeier; Katalin Szebeni; Gregory A Ordway Journal: Brain Res Date: 2006-11-21 Impact factor: 3.252
Authors: Rungnapa Hirunsatit; Elizabeth D George; Barbara K Lipska; Hani M Elwafi; Lisa Sander; Carolyn M Yrigollen; Joel Gelernter; Elena L Grigorenko; Jaakko Lappalainen; Shrikant Mane; Angus C Nairn; Joel E Kleinman; Arthur A Simen Journal: Pharmacogenet Genomics Date: 2009-01 Impact factor: 2.089
Authors: Chris C Streeter; John Hennen; Yong Ke; J Eric Jensen; Ofra Sarid-Segal; Leanne E Nassar; Clifford Knapp; Angela A Meyer; Tae Kwak; Perry F Renshaw; Domenic A Ciraulo Journal: Psychopharmacology (Berl) Date: 2005-10-19 Impact factor: 4.530
Authors: Marisa M Silveri; Jennifer T Sneider; David J Crowley; Michael J Covell; Deepa Acharya; Isabelle M Rosso; J Eric Jensen Journal: Biol Psychiatry Date: 2013-03-14 Impact factor: 13.382
Authors: Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf Journal: CNS Drugs Date: 2004 Impact factor: 5.749